datma Launches Federated Biomarker Explorer for Health Systems
datma has introduced Federated Biomarker Explorer for Health Systems, a tool designed for hospitals, cancer centers, and laboratories to gauge pharmaceutical demand for their healthcare data without sharing patient records or committing resources. The system allows institutions to determine whether their datasets align with active research needs before entering into formal agreements.
datma, based in Beaverton, Oregon, develops federated systems for healthcare data access. Its flagship platform, datma.FED, is structured as a marketplace where hospitals and labs keep control of their data but allow secure, privacy-preserving queries from pharmaceutical and life sciences users. The platform combines multimodal data harmonization, federated query capabilities, and AI-enabled tools to support evidence generation for oncology research and precision medicine.
The release extends datma’s Federated Biomarker Explorer, first rolled out in July for pharmaceutical users. That earlier version gave pharma teams free access to assess biomarker coverage across datma’s federated real-world data network, providing aggregate, cohort-level insights filterable by clinical and demographic attributes. It was designed for early feasibility checks, allowing users to see whether a target biomarker or patient population exists across participating cohorts before committing resources. It allowed feasibility assessments without IT support, contracting, or data integration. If alignment was found, data could then be linked securely within datma.FED for federated queries and analysis, all without centralizing data.
The new health system-facing tool complements that application, enabling bidirectional validation: pharmaceutical companies can evaluate feasibility, while health systems can preview demand for their datasets.
Participating institutions submit high-level metadata, such as cancer types, biomarker results, and cohort sizes, but no patient-level data. This information becomes visible to vetted pharmaceutical users conducting feasibility searches. When demand is confirmed, datma alerts the health system directly, giving it the option to join datma.FED under clear use cases. Participation remains optional and can be withdrawn at any stage.
The Federated Biomarker Explorer for Health Systems is available for early access registration.
Topic: Next-Gen Tools
